Both the CLIA DiaSorin Liaison SARS-CoV-2 S1/S2 IgG, the first serology test for SARS-CoV-2 approved by Health Canada, and the LFIA NADAL COVID-19 IgG/IgM specifically target antibodies to the S protein (13, 14). This evidence concerns the gene PROS1 and COVID-19.